Galectin Therapeutics (GALT) Preferred Shares (2010 - 2026)
Galectin Therapeutics' (GALT) quarterly Preferred Shares came in at $480000.0 in Q1 2026, down 4.0% year-on-year from $500000.0 in Q1 2025, and down 2.04% quarter-over-quarter from $490000.0 in Q4 2025.
Galectin Therapeutics (GALT) Preferred Shares (2010 - 2026) Analysis & Trends
Galectin Therapeutics' Preferred Shares history runs 17 years deep, the most recent figure standing at $480000.0 for Q1 2026.
- On a quarterly basis, Preferred Shares fell 4.0% year-over-year to $480000.0 in Q1 2026; TTM through Mar 2026 was $480000.0, a 4.0% decrease from a year earlier, with the FY2025 full-year figure at $490000.0, down 2.0% from the prior year.
- Preferred Shares retreated to $480000.0 in Q1 2026 per GALT's latest filing, from $490000.0 in the prior quarter.
- Across five years, Preferred Shares topped out at $527000.0 in Q1 2022 and bottomed at $480000.0 in Q1 2026.
- The 5-year median for Preferred Shares is $500000.0 (2023), against an average of $502176.5.
- Across the five-year window, Preferred Shares changed 0.0% in 2022 and decreased 4.0% in 2026, its largest moves.
- Year by year, Preferred Shares stood at $510000.0 in 2022, then declined by 1.96% to $500000.0 in 2023, then changed by 0.0% to $500000.0 in 2024, then dropped by 2.0% to $490000.0 in 2025, then retreated by 2.04% to $480000.0 in 2026.
- Per Business Quant, the three latest GALT Preferred Shares figures stand at $480000.0 (Q1 2026), $490000.0 (Q4 2025), and $490000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,102.16 Bn | 67,101.87 Bn | - | - |
| 2 | Nanobiotix | 1,909.44 Bn | 1,909.38 Bn | - | - |
| 3 | Akari Therapeutics | 989.71 Bn | 989.71 Bn | - | - |
| 4 | BeOne Medicines | 471.58 Bn | 466.79 Bn | 1.35 Bn | - |
| 5 | Vertex Pharmaceuticals | 121.97 Bn | 114.72 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 69.93 Bn | 61.18 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.68 Bn | 62.68 Bn | - | - |
| 8 | Argenx Se | 55.80 Bn | 50.61 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.37 Bn | 34.36 Bn | 959.66 Mn | - |
| 10 | Galectin Therapeutics | 221.69 Mn | 221.69 Mn | - | 480,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 480,000.00 |
| Dec 31, 2025 | 490,000.00 |
| Sep 30, 2025 | 490,000.00 |
| Jun 30, 2025 | 490,000.00 |
| Mar 31, 2025 | 500,000.00 |
| Dec 31, 2024 | 500,000.00 |
| Sep 30, 2024 | 500,000.00 |
| Jun 30, 2024 | 500,000.00 |
| Mar 31, 2024 | 500,000.00 |
| Dec 31, 2023 | 500,000.00 |
| Sep 30, 2023 | 510,000.00 |
| Jun 30, 2023 | 510,000.00 |
| Mar 31, 2023 | 510,000.00 |
| Dec 31, 2022 | 510,000.00 |
| Sep 30, 2022 | 510,000.00 |
| Jun 30, 2022 | 510,000.00 |
| Mar 31, 2022 | 527,000.00 |
| Dec 31, 2021 | 527,000.00 |
| Sep 30, 2021 | 527,000.00 |
| Jun 30, 2021 | 527,000.00 |